We’re pouring billions into cleaning up biological trash while almost completely ignoring the pipes. It’s like a city dealing with a massive sewage leak by buying more expensive mops instead of fixing the infrastructure. In longevity science, we’ve become obsessed with the mops.

Current funding is stuck in an "Aggregate-First" loop. We’ll fund a hundred more trials to clear amyloid or tau, or chase senolytics that act like a blunt hammer on a surgical problem, but we’re neglecting the Rab-mediated vesicular network. These aren't just "Parkinson’s genes"; they’re the air traffic controllers for every eukaryotic cell. When kinases like LRRK2 hyper-phosphorylate these Rabs, the cell's entire spatial organization falls apart. The lysosome doesn’t just get "old"—it starves because the transport trucks were sent to a dead end.

I don't understand why we’re so hesitant to fund dynamic organelle mapping. We prioritize static snapshots—histology, proteomics, GWAS hits—mostly because they’re easy to quantify in a grant report. But aging is a kinetic failure. It’s a breakdown in the speed and accuracy of intracellular transport. We've got to shift funding toward high-throughput assays that can measure endolysosomal flux in real-time across a lifespan.

If we’re serious about healthspan, we need to move past the "debris phase." That means a coordinated pivot toward cellular logistics. Labs need to stop working in silos on their favorite orphan protein and start mapping the cellular highway together. Is neurodegeneration a disease, or just what happens when the cellular supply chain goes on a permanent strike? Until our funding reflects that reality, we’re just paying billions to watch the pipes burst in higher resolution. It’s time to stop studying the stains and start studying the flow.